U.S. Markets closed
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • Dow 30

    33,212.96
    +575.77 (+1.76%)
     
  • Nasdaq

    12,131.13
    +390.48 (+3.33%)
     
  • Russell 2000

    1,887.86
    +49.62 (+2.70%)
     
  • Crude Oil

    115.13
    +1.04 (+0.91%)
     
  • Gold

    1,851.00
    +3.40 (+0.18%)
     
  • Silver

    22.13
    +0.16 (+0.75%)
     
  • EUR/USD

    1.0731
    -0.0002 (-0.0215%)
     
  • 10-Yr Bond

    2.7430
    -0.0130 (-0.47%)
     
  • Vix

    25.73
    -1.77 (-6.44%)
     
  • GBP/USD

    1.2630
    +0.0025 (+0.1970%)
     
  • USD/JPY

    127.1000
    -0.0020 (-0.0016%)
     
  • BTC-USD

    28,858.46
    -465.88 (-1.59%)
     
  • CMC Crypto 200

    626.11
    -3.39 (-0.54%)
     
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • Nikkei 225

    26,781.68
    +176.84 (+0.66%)
     

Royalty Pharma Announces 12% Dividend Increase

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2022 of $0.19 per Class A share, reflecting a 12% increase in the company’s quarterly dividend over the previous quarter’s dividend.

The dividend will be paid on March 15, 2022, to shareholders of record at the close of business on February 18, 2022.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 40 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnson’s Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com